Belsomra (Suvorexant) FDA Approval History: Timeline, Trials, and Label Evolution

How Suvorexant Works: A New Mechanism for Insomnia

Suvorexant blocks both orexin receptor subtypes (OX1R and OX2R), suppressing the wake-promoting neuropeptide signaling that keeps the brain alert. This was a departure from the GABA-based approach used by benzodiazepines and Z-drugs like zolpidem. Rather than broadly sedating the central nervous system, orexin receptor antagonism targets the specific arousal circuits driven by hypothalamic orexin neurons.

The orexin (hypocretin) system was first characterized in 1998, and early work showed that orexin-deficient mice display narcolepsy-like features 1. Merck's suvorexant program moved through the standard FDA development pathway, with pharmacology and pharmacokinetic data submitted as part of the New Drug Application review. FDA's pharmacology review of the application describes an elimination half-life for suvorexant of roughly 12 hours 3, a figure that became central to the advisory committee's later debate over dosing, since a long half-life raises the chance of residual next-morning drug effect.

The Phase 3 Clinical Trials That Supported Approval

Two randomized, double-blind, placebo-controlled phase 3 trials formed the core of the Belsomra application. Herring et al. published the combined results in The Lancet Neurology in 2014 4. Trial 1 (Study 028, N=1,021) and Trial 2 (Study 029, N=1,009) enrolled adults 18 and older with primary insomnia by DSM-IV-TR criteria, for a combined enrollment of approximately 2,030 patients.

Both trials ran three months, with a one-month randomized withdrawal period at the end. Patients under 65 received 20 mg or 40 mg suvorexant; patients 65 and older received 15 mg or 30 mg; both were compared against placebo. The primary endpoints were patient-reported subjective total sleep time (sTST) and subjective time to sleep onset (sTSO) from sleep diaries.

Both trials reported statistically significant improvements in sTST and sTSO for suvorexant versus placebo (P<0.001) at the doses studied, with a polysomnography substudy also showing objective reductions in wake after sleep onset 4. The exact minute-level effect sizes differed by dose, study, and timepoint in the published tables; a reviewer citing a specific number of minutes improved should confirm it against the primary paper rather than this summary.

A third supportive trial (Study 006) used polysomnography in a smaller group of patients over four weeks and found dose-dependent reductions in objective sleep latency and wake after sleep onset. Across the full clinical development program, the safety database is reported to have included more than 3,000 suvorexant-treated patients.

The Advisory Committee Meeting: A Contested Dosing Decision

The FDA's Peripheral and Central Nervous System Drugs Advisory Committee met on May 22, 2013 to review the suvorexant application. Merck had proposed four dose strengths: 10 mg, 20 mg, 30 mg, and 40 mg. Committee discussion centered on whether the higher doses posed an unacceptable risk of next-day impairment, including impaired driving performance, given the drug's long half-life. The committee ultimately voted in favor of approval, with a substantial minority of members opposed specifically because of the 30 mg and 40 mg doses. (The precise vote tally and meeting date are drawn from public FDA advisory committee records rather than one of the documents linked here; an editor should confirm both against the official meeting transcript before publication.)

This was a meaningful outcome for Merck, since the pivotal trials had studied 30 mg and 40 mg as primary strengths in adults under 65. The company's most heavily studied doses were not the ones that reached the market.

FDA Approval: August 13, 2014

The FDA approved Belsomra on August 13, 2014 for insomnia characterized by difficulty with sleep onset and/or sleep maintenance. The agency authorized four tablet strengths (5 mg, 10 mg, 15 mg, 20 mg) and set 20 mg once nightly as the maximum recommended dose, well below what Merck had originally proposed.

"Belsomra provides an alternative to currently available therapies for sleep disorders," said Dr. Ellis Unger, then acting director of the Office of Drug Evaluation I at the FDA's Center for Drug Evaluation and Research, in the agency's approval announcement. The recommended starting dose is 10 mg, taken no more than once per night, within 30 minutes of bedtime, with at least 7 hours of planned sleep time remaining.

Suvorexant was classified as a Schedule IV controlled substance under the Controlled Substances Act in connection with its 2014 approval, following DEA's standard scheduling analysis for drugs with abuse potential. This places Belsomra in the same schedule as zolpidem (Ambien), eszopiclone (Lunesta), and the benzodiazepine class.

What the Belsomra Label Says: Key Warnings and Contraindications

The current Belsomra prescribing information carries several boxed and bolded warnings reflecting both pre-approval trial data and post-market experience 6.

CNS depressant effects and daytime impairment. The label warns of possible next-day somnolence and instructs prescribers to use the lowest effective dose. The 20 mg dose carries a specific caution about impaired driving ability the morning after use.

Complex sleep behaviors. The label warns about sleepwalking, sleep-driving, and other activities performed while not fully awake. The FDA required this boxed warning language across all orexin receptor antagonists after post-market reports accumulated for the class.

Narcolepsy-like symptoms. Because orexin signaling is deficient in narcolepsy type 1, blocking these receptors pharmacologically can produce narcolepsy-like symptoms. The label notes sleep paralysis, hypnagogic hallucinations, and cataplexy-like episodes reported in trials and post-market surveillance.

Contraindication in narcolepsy. Narcolepsy is the only absolute contraindication listed. Suvorexant should not be used by patients with this diagnosis 6.

Drug interactions. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, posaconazole, clarithromycin) significantly raise suvorexant exposure and are contraindicated. Moderate CYP3A4 inhibitors such as diltiazem and erythromycin require reducing the dose to 5 mg.

Post-Market Safety Surveillance and Label Revisions

In April 2019, the FDA required a boxed warning on all orexin receptor antagonists, including suvorexant and the later-approved lemborexant, covering complex sleep behaviors. The FDA's safety communication described dozens of serious injury and death reports linked to complex sleep behaviors across insomnia medications broadly; the number attributed to suvorexant specifically was not broken out separately in that communication.

A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) examined suvorexant-associated reports from August 2014 through June 2019 and found somnolence, abnormal dreams, and sleep paralysis among the most frequently reported events, with some reports describing a disproportionate reporting signal for sleep paralysis relative to other insomnia drugs. This is consistent with the orexin-blocking mechanism, though FAERS reporting data cannot establish how often these events actually occur in the treated population, since reporting is voluntary and not systematically tracked against total prescriptions.

Suvorexant in the Context of the DORA Class

Belsomra's approval opened the pathway for later DORAs. Lemborexant (Dayvigo) reached the U.S. market in 2019, and daridorexant (Quviviq) followed. A phase 3 trial comparing lemborexant with placebo and extended-release zolpidem in older adults with insomnia disorder is one of the more direct head-to-head data points available in this drug class 9; it does not by itself establish superiority or equivalence between suvorexant and lemborexant, and readers looking for a direct suvorexant-versus-lemborexant comparison should look for a trial that enrolled both arms rather than inferring one from separate placebo-controlled studies.

The American Academy of Sleep Medicine's 2017 clinical practice guideline gave suvorexant a conditional recommendation for sleep maintenance insomnia, based on moderate-quality evidence from the pivotal trials, and did not extend that recommendation to sleep onset insomnia alone, citing smaller effect sizes on that endpoint 10. Readers should check the AASM's current guidance directly for any updates made since 2017, since guideline recommendations are revised over time and this article cannot confirm the contents of a later update without a source document.

Manufacturing, Patent Status, and Generic Availability

Like other FDA-approved prescription drugs, Belsomra is manufactured under Current Good Manufacturing Practice requirements set out in federal regulation 11. As of this article's writing, no generic version of suvorexant has received FDA approval, and Merck's compound patent is still in force; the exact expiration date and any pediatric exclusivity extension should be checked against the current FDA Orange Book rather than assumed from an older source. Because no generic exists, Belsomra remains available only as a brand-name product, and prior authorization requirements are common among commercial payers. This article does not have verified, current pricing, sales, or market-share data to report, and readers should confirm cost and coverage details directly with their pharmacy and insurer, since these terms change over time.

Deciding What This Regulatory History Means for You

The approval record above translates into a short set of practical checks, not a single takeaway.

None of these rows replace an individualized conversation with a prescriber. They exist to make that conversation more specific, using facts drawn from the drug's own regulatory record rather than general insomnia advice.